Biopharmaceutical MannKind, which has its headquarters in Westlake Village, is positioning itself as a med-tech platform. (Courtesy photo) MannKind has once again disappointed its short-sellers after news of a $105 million licensing deal with Maryland-based United Therapeutics sent shares soaring more than 140 percent. MannKind announced the deal just weeks from tripping over a $20…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
